Test Directory

The NGS Myeloid Cancer Panel is intended for use to help guide health care professionals in cancer treatment management for patients with myeloid disorders associated with Acute Myeloid Leukemia (AML), Myeloid Dysplastic Syndrome (MDS), Myeloproliferative Neoplasms (MPN) and Chronic Myeloid Leukemia (CML) in accordance with professional guidelines. The identification of genomic variants will identify patients who may benefit from treatment with specific FDA-approved targeted therapies, or in the use of other targeted oncology therapies. The results may also identify patient opportunities for participation in clinical trials.

Presence of FLT3-ITD or FLT3-TKD mutations in AML provide prognostic information, to aid in the determination of therapeutic regimen.

Transport to the laboratory refrigerated. 

• Any specimen with leakage on the outside of the container will be rejected. Ensure the lid is tightly closed.
• Any specimen collected in an outdated collection vial will be rejected.

 Myeloid Cancer Panel by NGS & FLT3 Gene Mutation Analysis with Interpretation

• FLT3 Mutation Test
  • Internal Tandem Duplications (ITD) in exons 14 and 15 of FLT3 gene
  • Tyrosine Kinase Domain mutation D835Y is exon 20 of FLT3 gene
• NGS Myeloid Panel
  • Detection of single nucleotide variants (SNV) and Insertions-Deletions (Indels) in 40 DNA genes; ABL1, ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, IKZF1, JAK2, KIT, KRAS, MPL, MYD88, NF1, NPM1, NRAS, PHF6, PRPF8, PTPN11, RB1, RUNX1, SETBP1, SF3B1, SH2B3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2
  • Detection of RNA fusions from 29 driver genes: ABL1, ALK, BCL2, BRAF, CCND1, CREBBP, EGFR, ETV6, FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A (MLL), MECOM, MET, MLLT10, MLLT3, MYBL1, MYH11, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM15, RUNX1, TCF3, TFE3